Knee tissue - Medium Biopsy 1-3 cm

Biopsy

Report in 288Hrs

At Home

No Fasting Required

Details

Joint tissue biopsy.

₹370₹529

30% OFF

Knee Tissue - Medium Biopsy (1-3 cm)

Why is it done?
- A knee tissue biopsy is a diagnostic procedure that involves removing a small tissue sample (1-3 cm) from the knee joint or surrounding structures for microscopic examination and laboratory analysis.
- Primary Indications: Diagnosis of unexplained knee joint inflammation, suspected synovitis, chronic joint pain of unknown etiology, or ruling out malignancy in knee lesions.
- When performed: When imaging studies (MRI, ultrasound) show abnormalities requiring tissue diagnosis, when infectious or inflammatory knee conditions are suspected, or when conservative management has failed to identify the underlying cause.
- Common target areas: Synovial membrane, joint cartilage, meniscus, ligaments, or soft tissue masses within the knee joint capsule.
Normal Range
- Normal tissue characteristics: Intact synovial lining with minimal inflammatory cells (fewer than 2,000 white blood cells per microliter), normal cartilage matrix with organized collagen architecture, absence of malignant cells, and no evidence of microorganisms or foreign material.
- Microscopic findings (Normal): Single layer or thin synovial membrane with fibroblasts, normal vascular architecture, minimal fibrin deposition, and absence of inflammatory infiltrates or atypical cells.
- Interpretation of Normal Results: Indicates absence of infection, malignancy, significant inflammatory disease, or degenerative changes in the sampled tissue. Does not necessarily exclude systemic conditions or pathology in unsampled areas.
- Units of measurement: Tissue sample size: 1-3 cm; Cell counts: cells per microliter (µL); Microscopic features: descriptive histopathology; Culture results: presence/absence of organisms or growth.
Interpretation
- Inflammatory findings: Increased inflammatory cells (>2,000 WBC/µL) suggest inflammatory arthropathy such as rheumatoid arthritis, seronegative spondyloarthropathy, or reactive arthritis. Presence of specific cell types (lymphocytes, neutrophils, macrophages) indicates disease type and severity.
- Infectious findings: Culture-positive results indicate bacterial, viral, fungal, or mycobacterial infection. Presence of organisms on special stains (Gram, acid-fast, GMS) confirms specific pathogens. Requires immediate clinical intervention and antibiotic therapy.
- Malignant findings: Atypical or frankly malignant cells indicate primary or secondary knee malignancy (synovial sarcoma, lymphoma, metastatic disease). Requires oncologic consultation and staging studies.
- Degenerative findings: Chondrocyte loss, fibrillation, collagen disorganization, and bone remodeling indicate osteoarthritis or chronic cartilage damage. Severity correlates with clinical dysfunction.
- Factors affecting interpretation: Biopsy site location (may not represent entire joint), timing of biopsy relative to disease onset, prior treatments, contamination during collection, and specimen adequacy. Sample size (1-3 cm) is considered medium volume, suitable for most diagnostic purposes.
- Clinical significance: Results provide definitive diagnosis in 80-90% of cases with inflammation. Negative findings do not exclude systemic disease and may require repeat biopsy or additional imaging if clinical suspicion remains high.
Associated Organs
- Primary organ system: Musculoskeletal system, specifically the knee joint complex including synovial membrane, articular cartilage, menisci, ligaments, and associated soft tissues.
- Conditions commonly diagnosed: Rheumatoid arthritis, osteoarthritis, septic arthritis (bacterial, fungal, TB), synovitis, bursitis, gout (crystal arthropathy), psoriatic arthritis, juvenile idiopathic arthritis, Lyme arthritis, tuberculosis of the knee, fungal infections (candidiasis, histoplasmosis), and synovial sarcoma.
- Associated systemic diseases: Systemic lupus erythematosus, systemic sclerosis, Behçet's disease, sarcoidosis, and other connective tissue disorders that manifest with knee involvement.
- Potential complications of abnormal results: Chronic joint inflammation leading to cartilage destruction and permanent disability, progression of infection to osteomyelitis or sepsis, malignancy spread and metastatic disease, and loss of joint mobility and function.
- Complications of the biopsy procedure: Infection (including iatrogenic infection), bleeding or hematoma, nerve or vessel injury, allergic reaction to anesthetic, and transient increased pain or swelling (usually resolves within 24-48 hours).
Follow-up Tests
- If infection is identified: Blood cultures, antibiotic sensitivity testing, blood count and comprehensive metabolic panel, imaging (MRI/CT) to assess extent of infection, repeat biopsy if needed for organisms not initially cultured, and systemic infection markers (ESR, CRP).
- If inflammatory arthropathy is identified: Rheumatologic panel (rheumatoid factor, anti-CCP antibodies, ANA), inflammatory markers (ESR, CRP), complete blood count, liver and kidney function tests, imaging studies (X-rays for joint damage), and possible second opinion from rheumatologist.
- If malignancy is identified: Oncologic consultation, full body imaging (CT/MRI/PET), immunohistochemical staining, molecular testing (cytogenetics, gene expression profiling), staging studies, and multidisciplinary tumor board review.
- If results are inconclusive: Repeat biopsy (different site or larger sample), advanced imaging (MRI with advanced sequences), synovial fluid analysis, and consideration of empiric therapy based on clinical presentation.
- Monitoring frequency: For confirmed inflammatory disease: 4-6 weeks after diagnosis to assess treatment response, then every 3 months for first year, then annually. For infection: weekly until infection cleared, then monthly for 3 months. For malignancy: per oncologic protocol (typically every 3 months initially).
- Complementary tests: Synovial fluid analysis (cell count, crystals, glucose, protein), imaging reassessment (ultrasound or MRI), functional assessment tests, and patient-reported outcome measures for disease monitoring.
Fasting Required?
- Fasting requirement: No, fasting is not required for this biopsy procedure.
- Pre-procedure preparation: Normal breakfast may be consumed unless general anesthesia is planned (then follow standard NPO guidelines: no food for 6 hours, clear liquids up to 2 hours before procedure). Wear loose, comfortable clothing that allows access to the knee.
- Medications to avoid: Discontinue anticoagulants (warfarin) 3-5 days before procedure if possible; continue aspirin unless specifically instructed otherwise. NSAIDs (ibuprofen, naproxen) may be continued but notify physician. Stop all blood thinners (clopidogrel, dabigatran) 24-48 hours before, per physician instruction.
- Other pre-procedure instructions: Obtain informed consent and review procedure risks; provide complete medical history including allergies (especially to local anesthetics); arrange for transportation home as procedure may involve sedation. Avoid lotion or makeup on the knee area.
- Post-procedure care: Rest with leg elevated for 24-48 hours, apply ice for 15-20 minutes every 2-3 hours, take prescribed pain medications as directed, and avoid strenuous activity for 1-2 weeks. Resume anticoagulants per physician instruction (typically 24 hours after biopsy).
- When to seek immediate medical attention: Severe pain not controlled by medications, excessive swelling or fluid drainage, signs of infection (fever >101°F, increased warmth, redness, pus), significant bleeding or hematoma, or severe weakness/numbness in the leg.

How our test process works!